Researchers at Johns Hopkins unveiled an AI‑driven liquid biopsy that uses genome‑wide cfDNA fragmentation patterns—fragmentomics—to detect liver fibrosis, cirrhosis, and other chronic liver disease markers. In a pilot study the assay differentiated organ‑specific fragmentation signals and immune‑related changes, suggesting cfDNA fragmentomics can extend noninvasive diagnostics beyond oncology. The work builds on prior fragmentomics efforts and was reported alongside a broader study showing cfDNA fragment patterns can identify non‑cancer liver disease. Commercial developers and academic groups view fragmentomics as a route to scalable screening tools for rising liver disease prevalence, but larger clinical validation and regulatory pathways remain to be established.